The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://tomashfbx465243.post-blogs.com/59528787/retatrutide-vs-tirzepatide-a-comparative-analysis